8-K: Akebia Therapeutics Secures Multi-Year Supply Deal for Vafseo with Major Dialysis Provider

Akebia Therapeutics has signed a multi-year commercial supply agreement with a leading dialysis organization to expand access to Vafseo (vadadustat) for patients on dialysis.

Summary

• Akebia Therapeutics has entered into a multi-year commercial supply agreement with a major dialysis provider.
• This agreement will enable broader access to Vafseo (vadadustat) for patients undergoing dialysis.
• The contract allows physicians to prescribe Vafseo to dialysis patients where clinically appropriate.
• Vafseo is expected to be available in the U.S. starting in January 2025.
• The FDA approved Vafseo in March 2024 for treating anemia due to chronic kidney disease in adults on dialysis for at least three months.
• The Center for Medicare & Medicaid Services granted Transitional Drug Add-On Payment Adjustment reimbursement for Vafseo starting January 1, 2025.
• A Level II Healthcare Common Procedure Coding System code has been issued for billing the product for Medicare enrollees.

Sentiment

Score: 7

Explanation: The document is positive due to the commercial supply agreement and expected launch of Vafseo, but the boxed warning and potential risks temper the overall sentiment.

Positives

• The commercial supply agreement with a major dialysis provider significantly expands the potential market for Vafseo.
• The agreement enables physicians to prescribe Vafseo to a large patient population.
• Medicare reimbursement starting January 1, 2025, will facilitate patient access to Vafseo.
• Vafseo is a new treatment option for anemia in dialysis patients.

Negatives

• Vafseo has a boxed warning regarding increased risk of death, myocardial infarction, stroke, venous thromboembolism, and thrombosis of vascular access.
• The drug is not recommended for patients with active malignancies.
• There are specific warnings and precautions regarding hepatotoxicity, hypertension, seizures, and gastrointestinal erosion.
• Vafseo is not indicated for use in patients with anemia due to CKD not on dialysis.

Risks

• There are risks associated with the commercial launch of Vafseo, including market acceptance and reimbursement.
• The competitive landscape for anemia treatments could impact Vafseo's success.
• There are potential risks related to manufacturing, supply chain, and quality control.
• The company faces risks related to regulatory decisions and the potential for early termination of collaborations.
• The drug has a boxed warning for serious adverse events.

Future Outlook

Akebia expects Vafseo to be available in the U.S. in January 2025 and believes the supply agreement will significantly broaden access to the drug.

Management Comments

• Nik Grund, Chief Commercial Officer, stated that expanding access to Vafseo is a priority of their commercial launch.
• Nik Grund believes the supply agreement will significantly broaden access to Vafseo among physicians and for its more than 200,000 patients.

Industry Context

This agreement positions Akebia to compete in the market for anemia treatments in dialysis patients, where there is a need for new options. The deal with a major dialysis provider is a significant step in the commercialization of Vafseo.

Comparison to Industry Standards

• The agreement with a major dialysis provider is a significant step for Akebia, similar to other pharmaceutical companies securing distribution channels for their products.
• The approval and reimbursement for Vafseo are comparable to other treatments for anemia in dialysis patients, such as erythropoietin stimulating agents (ESAs).
• The boxed warning for Vafseo is similar to warnings for ESAs, highlighting the risks associated with this class of drugs.
• The company will need to demonstrate that Vafseo can compete effectively with existing treatments in terms of efficacy, safety, and cost.

Stakeholder Impact

• Shareholders will likely view the commercial supply agreement positively.
• Patients on dialysis will have a new treatment option for anemia.
• Physicians will have another tool for managing anemia in their dialysis patients.
• The dialysis organization will be able to offer Vafseo to its patients.

Next Steps

• Akebia will focus on the commercial launch of Vafseo in the U.S. in January 2025.
• The company will work to ensure that physicians can prescribe Vafseo to eligible patients.
• Akebia will monitor the market uptake of Vafseo and its impact on patient outcomes.

Key Dates

Keywords

Vafseo, vadadustat, Akebia Therapeutics, dialysis, anemia, chronic kidney disease, commercial supply agreement, Medicare, reimbursement, FDA approval